Cargando…
Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases
INTRODUCTION: Inclusion body myositis (IBM) is a slowly progressive degenerative inflammatory disorder affecting both proximal and distal muscles. Immunosuppressive therapies are generally ineffective in the treatment of this disorder, and most patients are resistant to steroid therapy. Some benefit...
Autores principales: | Cherin, Patrick, Delain, Jean-Christophe, de Jaeger, Christophe, Crave, Jean-Charles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649754/ https://www.ncbi.nlm.nih.gov/pubmed/26600787 http://dx.doi.org/10.1159/000441490 |
Ejemplares similares
-
High-Dose Subcutaneous Immunoglobulins for the Treatment of Severe Treatment-Resistant Polymyositis
por: Patrick, Cherin, et al.
Publicado: (2014) -
Corrigendum to “High-Dose Subcutaneous Immunoglobulins for the Treatment of Severe Treatment-Resistant Polymyositis”
por: Cherin, Patrick, et al.
Publicado: (2015) -
Subcutaneous immunoglobulins for the treatment of a patient with antisynthetase syndrome and secondary chronic immunodeficiency after anti-CD20 treatment: a case report
por: Cherin, Patrick, et al.
Publicado: (2017) -
Scleromyxedema with Subcutaneous Nodules: Successful Treatment with Thalidomide and Intravenous Immunoglobulin
por: Dolenc-Voljč, M., et al.
Publicado: (2013) -
Erythromelanosis Follicularis Faciei: A Case Report and Review of the Literature
por: Al Hawsawi, Khalid, et al.
Publicado: (2015)